Best response | Overall (N=33) (%) | Dose level 1 (n=3) (%) | Dose level 2 (n=30) (%) | CRC (n=6) (%) | Solid tumor* (n=6) (%) | Ovarian (n=8) (%) | RCC (n=7) (%) | Melanoma (n=6) (%) |
CR | 2 (6) | 0 | 2 (7) | 0 | 0 | 0 | 0 | 2 (33)† |
Partial response | 3 (9) | 0 | 3 (10) | 0 | 1 (16.7) | 0 | 1 (14) | 1 (17) |
Stable disease | 8 (24) | 1 (33) | 7 (23) | 0 | 2 (33) | 2 (25) | 4 (57) | 0 |
Progressive disease | 15 (45) | 2 (67) | 13 (43) | 3 (50) | 3 (50) | 6 (75) | 2 (29) | 1 (17) |
Unknown | 5 (15) | 0 | 5 (17) | 3 (50) | 0 | 0 | 0 | 2 (33) |
*Solid tumors included one patient with mesothelioma, one patient with breast cancer, and one patient with sarcoma in cohort 1, and two patients with mesothelioma and one patient with breast cancer in cohort 2.
†Both patients with CR had melanoma and were in cohort 2 (dose level 2).
CR, complete response; CRC, colorectal cancer; RCC, renal cell carcinoma.